From the Corporate Update:
"The Directors have reviewed a number of diverse investment opportunities during the half year, that included but were not limited to the life sciences sector".
"Given the opportunities currently under review the Board is confident that a transaction is likely to occur in the near term".
Perhaps we could see some action before the end of this FY?
Ann: Appendix 4D and Half Year Report, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.50 |
Change
0.030(0.86%) |
Mkt cap ! $708.4M | |||
| Open | High | Low | Value | Volume |
| $3.44 | $3.53 | $3.44 | $997.9K | 284.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9598 | $3.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.51 | 584 | 1 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| ACL (ASX) Chart |
